Q3’25Revenue at ₹2339 million up46 % Y-O-Y
Q3’25 Net Profit at ₹629million up 40% Y-O-Y
Highlights for the Quarter Y-O-Y:
- Revenue at ₹2339 million, a growth of 46%
- Domestic Sales grew by 20%
- Export Sales grew by more than 10X due to low base
- Profit After Tax was up by 40%
Highlights for the Nine Months:
- Revenueat ₹6274million,a growth of 13%
- Domestic Sales grew by 1%
- Export Sales grew by 96% due to low base
- Profit After Tax was up by 27%
MUMBAI | 12th NOVEMBER 2025 — Sanofi Consumer Healthcare India Limited (BSE:544250 I NSE: SANOFICONR) releases its financial results for the third quarter demonstrating growth across key business segments.
Driven by exports and domestic business, revenue growth for the quarter stood at 46% year-on-year for 2025. Profit after tax (PAT) for Q3 reached ₹629 million, a 40% increase over year-on-year basis.
Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited: “Our third-quarter results reflect the strength of our diversified portfolio driving sustained growth momentum this quarter. The domestic business demonstrates good performance, with exports providing additional impetus to revenue growth. All our voluntarily recalled products have successfully re-established their market presence within the year. Anchored in science and guided by purpose, we remain committed to making self-care simpler, more accessible and more effective for every consumer.”
Note: Quarter and nine months are not directly comparable due to the demerger and voluntary recall of certain variants of key brands in the domestic market.
——————————————————————————–
